ENDRA Life Sciences (NDRA) Operating Leases (2019 - 2026)

ENDRA Life Sciences (NDRA) has reported Operating Leases for 8 consecutive years, with $290630.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 47.87% year-over-year to $290630.0 in Q2 2026; TTM through Jun 2026 was $290630.0, a 47.87% decrease from a year earlier, with the FY2025 full-year figure at $362974.0, down 37.89% from the prior year.
• Operating Leases was $290630.0 for Q2 2026 at ENDRA Life Sciences, down from $327253.0 in the prior quarter.
• Over five years, Operating Leases peaked at $618735.0 in Q1 2022 and troughed at $237163.0 in Q3 2024.
• A 5-year average of $447286.8 and a median of $462892.5 in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 121.51% in 2025 and plunged 47.87% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $518147.0 in 2022, then fell by 29.38% to $365919.0 in 2023, then soared by 59.71% to $584419.0 in 2024, then sank by 37.89% to $362974.0 in 2025, then fell by 19.93% to $290630.0 in 2026.
• The last three Operating Leases figures came in at $290630.0 (Q2 2026), $327253.0 (Q1 2026), and $362974.0 (Q4 2025), per Business Quant data.